Teri Sarnowski
Psychiatric/Mental Health · San Francisco, CANPI 1346846615
Payments from drug & device makers
Across 174 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$645
- Otsuka America Pharmaceutical, Inc.$601
- Axsome Therapeutics, Inc.$324
- Sunovion Pharmaceuticals Inc.$260
- Lundbeck LLC$225
- Ironshore Pharmaceuticals Inc.$173
- plus $524 from 8 others
What the payments were for
- Food & beverage$2,65797%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $645 |
| Otsuka America Pharmaceutical, Inc. | 33 | $601 |
| Axsome Therapeutics, Inc. | 27 | $324 |
| Sunovion Pharmaceuticals Inc. | 20 | $260 |
| Lundbeck LLC | 11 | $225 |
| Ironshore Pharmaceuticals Inc. | 10 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $172 |
| Supernus Pharmaceuticals, Inc. | 5 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $94 |
| Alkermes, Inc. | 2 | $45 |
| Corium, LLC | 3 | $45 |
| Noven Therapeutics, LLC | 2 | $37 |
| Neuronetics, Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $14 |
How this compares
$2,751 in reported general payments places this provider in the 80th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 18 | $24,024 |
| Vilazodone Hcl | 26 | $1,791 |
| Duloxetine Hcl | 65 | $959 |
| Buspirone Hcl | 78 | $878 |
| Atomoxetine Hcl | 24 | $824 |
| Quetiapine Fumarate | 64 | $650 |
| Sertraline Hcl | 78 | $488 |
| Gabapentin | 47 | $481 |
| Trazodone Hcl | 74 | $479 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 48 | $463 |
| Prazosin Hcl | 31 | $451 |
| Bupropion Hcl SrBupropion Hcl | 22 | $405 |
| Bupropion XlBupropion Hcl | 34 | $359 |
| Fluoxetine Hcl | 58 | $297 |
| Clonazepam | 52 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $645 | $24,02418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in San Francisco
- Charles WilliamsonSan Francisco$10K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.